TORONTO and GATINEAU, QC, March 5,
2025 /CNW/ - Converge Technology Solutions Corp.
("Converge" or the "Company") (TSX:CTS) (FSE:0ZB)
(OTCQX:CTSDF) is pleased to provide its financial results for the
three months and fiscal year ended December
31, 2024. All figures are in Canadian dollars unless
otherwise stated.
Fourth Quarter 2024 Highlights (year-over-year, unless
otherwise noted):
- Gross sales1 of $1.11
billion, an increase of $27.4
million or 2.5%;
- Gross sales organic growth1 of 3.0% and gross profit
organic growth1 of (0.0%);
- Revenue of $680.8 million, an
increase of $29.7 million or
4.6%;
- Gross profit decreased 1.6% to $178.6
million, representing a gross margin of 26.7%;
- Adjusted EBITDA1 increased by 3.0% to $47.9 million;
- Cash from operating activities was $57.0
million, a decrease of $57.5
million, compared to $114.5
million for the comparative period in the prior year;
- Returned $20.6 million of capital
to shareholders1 as compared to $4.7 million return of capital to shareholders in
Q4 FY23; and
- Reduced net debt1 by $14.5 million from $127.9
million at Q3 2024; maintaining a leverage
ratio1 below 0.7x.
Fiscal Year 2024 Highlights (year-over-year,
unless otherwise noted):
- Gross sales1 of $4.12 billion, an
increase of $82.8 million or
2.1%;
- Gross sales organic growth1 of 2.3% and gross profit organic
growth1 of (0.7%);
- Revenue of $2.59 billion, a
decrease of $113.1 million or
(4.2%);
- Gross profit decreased 1.6% to $691.4
million, representing a gross margin of 26.7%;
- Adjusted EBITDA1 decreased by 1.7% to $167.3 million;
- Net loss of $181.0 million, an
increase in loss of $174.6 million,
driven by the non-cash impairment charge on the Germany segment of $176.1 million;
- Returned $82.3 million of capital
to shareholders1 as compared to
$23.5 million return of capital to
shareholders for the comparative period in prior year;
- Cash from operating activities was $269.4 million, an increase of $39.9 million, compared to $229.5 million for the comparative period in the
prior year; and
- Reduced net debt1 by $96.4 million to $113.4
million, from $209.8 million
at Q4 2023.
_________
|
1
|
This is a Non-IFRS
measure (including non-IFRS ratio or supplementary financial
measure) and not a recognized, defined or standardized measure
under IFRS. See the "Non-IFRS Financial Measures" section of this
press release for definitions, uses and a reconciliation of
historical non-IFRS financial measures to the most directly
comparable IFRS financial measures.
|
Financial Summary
|
Three months
ended
December 31,
|
|
Fiscal year
ended
December 31,
|
In $000s except per
share amounts
|
2024
$
|
2023
$
|
|
2024
$
|
2023
$
|
Gross
Sales1
|
1,106,055
|
1,078,663
|
|
4,120,717
|
4,037,921
|
Revenue
|
680,778
|
651,090
|
|
2,592,081
|
2,705,207
|
Gross profit
(GP)
|
178,629
|
181,529
|
|
691,442
|
702,880
|
Gross profit
(GP)%
|
26.2 %
|
27.9 %
|
|
26.7 %
|
26.0 %
|
Adjusted
EBITDA1
|
47,885
|
46,505
|
|
167,315
|
170,294
|
Adjusted EBITDA as a %
of GP1
|
26.8 %
|
25.6 %
|
|
24.2 %
|
24.2 %
|
Net loss
|
(9,174)
|
4,781
|
|
(180,986)
|
(6,393)
|
Adjusted net
income1
|
45,586
|
38,214
|
|
130,289
|
108,399
|
Adjusted
EPS1
|
0.23
|
0.19
|
|
0.66
|
0.53
|
Converge to be Acquired by H.I.G. Capital
On February 7, 2025, Converge
announced that it had entered into an arrangement agreement (the
"Arrangement Agreement") with an affiliate of H.I.G. Capital
("H.I.G."), whereby H.I.G will acquire all of the issued and
outstanding common shares (the "Common Shares") of the Company
(the "Transaction"). Under the terms of the Arrangement Agreement,
shareholders will receive $5.50 per
Common Share in cash, other than Common Shares held by certain
shareholders who enter into rollover equity agreements,
representing approximately 56% and 57% respective premiums to the
closing price and 30-day volume weighted average price of the
shares on the TSX on February 6,
2025, the last trading day prior to the date of the
announcement of the Transaction. The purchase price of the
Transaction values Converge at an enterprise value of approximately
C$1.3 billion. Upon completion of the
Transaction, the Company intends to apply to delist the Common
Shares from all public markets and cease to be a reporting issuer
under Canadian securities laws.
The Transaction is to be considered by shareholders at a special
meeting of shareholders to be held on April
10, 2025. A management information circular with respect to
the matters to be considered at that meeting will be filed by
Converge on SEDAR+ at www.sedarplus.ca, and will been mailed to
shareholders.
As a result of the proposed Transaction, the Company will not be
holding an earnings conference call and is suspending its practice
of providing its outlook for revenue, gross profit and Adjusted
EBITDA for the 2025 fiscal year. As part of the Arrangement
Agreement, Converge has agreed that its regular quarterly dividend
during the pendency of the Transaction will not be declared.
__________
|
1
|
This is a Non-IFRS
measure (including non-IFRS ratio or supplementary financial
measure) and not a recognized, defined or standardized measure
under IFRS. See the "Non-IFRS Financial Measures" section of this
press release for definitions, uses and a reconciliation of
historical non-IFRS financial measures to the most directly
comparable IFRS financial measures.
|
About Converge
Converge Technology Solutions Corp. is reimagining the way
businesses think about IT—a vision driven by people, for people.
Since 2017, we have focused on delivering outcomes-driven solutions
that tackle human-centered challenges. As a services-led,
software-enabled, IT & Cloud Solutions provider, we combine
deep expertise, local connections, and global resources to deliver
industry-leading solutions.
Through advanced analytics, artificial intelligence (AI), cloud
platforms, cybersecurity, digital infrastructure, and workplace
transformation, we empower businesses across industries to
innovate, streamline operations, and achieve meaningful results.
Our AIM (Advise, Implement, Manage) methodology ensures solutions
are tailored to our customers' specific needs, aligning with
existing systems to drive success without complexity.
Discover IT reimagined with Converge—where innovation meets
people. Learn more at convergetp.com.
Summary of Statements of Financial Position
(expressed in thousands of Canadian dollars)
|
December
31,
2024
$
|
|
December 31,
2023
$
|
Assets
|
|
|
|
Current
|
|
|
|
|
Cash
|
142,733
|
|
170,419
|
|
Trade and other
receivables
|
1,000,573
|
|
803,652
|
|
Inventories
|
62,938
|
|
73,166
|
|
Prepaid expenses
and other assets
|
30,728
|
|
26,528
|
|
|
1,236,972
|
|
1,073,765
|
Non-current
|
|
|
|
|
Investment in
associates
|
4,795
|
|
-
|
|
Unbilled receivables
and other assets
|
204,208
|
|
64,158
|
|
Property, equipment and
right-of-use assets, net
|
69,696
|
|
75,488
|
|
Intangible assets,
net
|
265,882
|
|
375,181
|
|
Goodwill
|
404,711
|
|
564,770
|
Total
assets
|
2,186,264
|
|
2,153,362
|
|
|
|
|
|
Liabilities
|
|
|
|
Current
|
|
|
|
|
Trade and other
payables
|
1,202,943
|
|
853,655
|
|
Other financial
liabilities
|
39,882
|
|
54,095
|
|
Deferred
revenue
|
81,109
|
|
59,325
|
|
Borrowings
|
639
|
|
1,664
|
|
Income taxes
payable
|
-
|
|
9,286
|
|
|
1,324,573
|
|
978,025
|
Non-current
|
|
|
|
|
Accrued liabilities and
other payables
|
184,514
|
|
60,339
|
|
Other financial
liabilities
|
34,174
|
|
57,668
|
|
Borrowings
|
255,464
|
|
378,007
|
|
Deferred tax
liabilities
|
28,804
|
|
67,168
|
Total
liabilities
|
1,827,529
|
|
1,541,207
|
|
|
|
|
|
Shareholders'
equity
|
|
|
|
|
Common
shares
|
555,521
|
|
599,434
|
|
Contributed
surplus
|
16,532
|
|
10,970
|
|
Accumulated other
comprehensive income
|
28,603
|
|
3,963
|
|
Deficit
|
(241,921)
|
|
(28,167)
|
Total equity
attributable to shareholders of Converge
|
358,735
|
|
586,200
|
Non-controlling
interest
|
-
|
|
25,955
|
|
358,735
|
|
612,155
|
Total liabilities
and shareholders' equity
|
2,186,264
|
|
2,153,362
|
Summary of Statements of Income and Comprehensive
Income
(expressed in thousands of Canadian
dollars)
|
Three months
ended
December 31,
|
|
Fiscal year
ended
December 31,
|
|
2024
$
|
|
2023
$
|
|
2024
$
|
|
2023
$
|
Revenue
|
|
|
|
|
|
|
|
Product
|
555,055
|
|
490,948
|
|
2,058,494
|
|
2,098,880
|
Service
|
125,723
|
|
160,142
|
|
533,587
|
|
606,327
|
Total
revenue
|
680,778
|
|
651,090
|
|
2,592,081
|
|
2,705,207
|
Cost of
sales
|
502,149
|
|
469,561
|
|
1,900,639
|
|
2,002,327
|
Gross
profit
|
178,629
|
|
181,529
|
|
691,442
|
|
702,880
|
Selling, general and
administrative expenses
|
134,040
|
|
137,451
|
|
534,918
|
|
541,118
|
Income before the
following
|
44,589
|
|
44,078
|
|
156,524
|
|
161,762
|
Depreciation and
amortization
|
20,283
|
|
29,212
|
|
89,665
|
|
111,451
|
Finance expense,
net
|
8,098
|
|
10,355
|
|
30,979
|
|
41,225
|
Acquisition,
integration, restructuring and other
|
5,737
|
|
2,679
|
|
16,429
|
|
13,648
|
Change in fair value of
contingent consideration
|
6,293
|
|
5,464
|
|
10,582
|
|
14,673
|
Share-based
compensation
|
1,185
|
|
954
|
|
5,858
|
|
3,692
|
Other loss (income),
net
|
237
|
|
(132)
|
|
1,357
|
|
(4,362)
|
Loss on loss of control
of Portage
|
-
|
|
-
|
|
117
|
|
-
|
Loss from investment in
associates
|
23,962
|
|
-
|
|
25,930
|
|
-
|
Impairment loss –
Germany segment
|
-
|
|
-
|
|
176,124
|
|
-
|
Loss before income
taxes
|
(21,206)
|
|
(4,454)
|
|
(200,517)
|
|
(18,565)
|
Income tax
recovery
|
(12,032)
|
|
(9,235)
|
|
(19,531)
|
|
(12,172)
|
Net (loss)
income
|
(9,174)
|
|
4,781
|
|
(180,986)
|
|
(6,393)
|
Net (loss) income
attributable to:
|
|
|
|
|
|
|
|
Shareholders of
Converge
|
(9,174)
|
|
5,861
|
|
(177,713)
|
|
(1,448)
|
Non-controlling
interest
|
-
|
|
(1,080)
|
|
(3,273)
|
|
(4,945)
|
|
(9,174)
|
|
4,781
|
|
(180,986)
|
|
(6,393)
|
Other comprehensive
(loss) income
|
|
|
|
|
|
|
|
Exchange differences on
translation of foreign operations
|
15,594
|
|
916
|
|
24,640
|
|
(9,745)
|
Comprehensive (loss)
income
|
6,420
|
|
5,697
|
|
(156,346)
|
|
(16,138)
|
Comprehensive (loss)
income attributable to:
|
|
|
|
|
|
|
|
Shareholders of
Converge
|
6,420
|
|
6,777
|
|
(153,073)
|
|
(11,193)
|
Non-controlling
interest
|
-
|
|
(1,080)
|
|
(3,273)
|
|
(4,945)
|
|
6,420
|
|
5,697
|
|
(156,346)
|
|
(16,138)
|
Adjusted
EBITDA1
|
47,885
|
|
46,505
|
|
167,315
|
|
170,294
|
Adjusted EBITDA as a
% of gross profit1
|
26.8 %
|
|
25.6 %
|
|
24.2 %
|
|
24.2 %
|
Summary of Statements of Cash Flows
(expressed in thousands of Canadian dollars)
|
Three months
ended
December 31,
|
Fiscal year
ended
December 31,
|
|
2024
|
|
2023
|
|
2024
|
|
2023
|
|
$
|
|
$
|
|
$
|
|
$
|
Cash flows from
operating activities
|
|
|
|
|
|
|
|
Net loss
|
(9,174)
|
|
4,781
|
|
(180,986)
|
|
(6,393)
|
Adjustments to
reconcile net loss to net cash from operating activities
|
|
|
|
|
|
|
|
Depreciation and
amortization
|
23,579
|
|
31,369
|
|
100,456
|
|
119,983
|
Unrealized foreign
exchange loss (gain)
|
197
|
|
(4)
|
|
1,077
|
|
(2,822)
|
Share-based
compensation
|
1,185
|
|
954
|
|
5,858
|
|
3,692
|
Finance expense, net
|
8,098
|
|
10,355
|
|
30,979
|
|
41,225
|
(Loss) gain on sale of property and equipment
|
14
|
|
335
|
|
87
|
|
(263)
|
Change in fair value of contingent consideration
|
6,293
|
|
5,464
|
|
10,582
|
|
14,673
|
Impairment loss –
Germany segment
|
-
|
|
-
|
|
176,124
|
|
-
|
Loss on loss of
control of Portage
|
-
|
|
-
|
|
117
|
|
-
|
Loss from investment
in associates
|
23,962
|
|
-
|
|
25,930
|
|
-
|
Income tax
recovery
|
(12,032)
|
|
(9,235)
|
|
(19,531)
|
|
(12,172)
|
|
42,122
|
|
44,289
|
|
150,693
|
|
157,923
|
Changes in non-cash
working capital items
|
16,822
|
|
71,888
|
|
148,464
|
|
90,746
|
|
58,944
|
|
116,177
|
|
299,157
|
|
248,669
|
Income taxes
paid
|
(1,971)
|
|
(1,696)
|
|
(29,776)
|
|
(19,129)
|
Cash from operating
activities
|
56,973
|
|
114,481
|
|
269,381
|
|
229,540
|
|
|
|
|
|
|
|
|
Cash flows from
(used in) investing activities
|
|
|
|
|
|
|
|
Purchase of (proceeds
from) property, equipment and intangible assets
|
206
|
|
(2,038)
|
|
(1,442)
|
|
(10,828)
|
Proceeds on disposal of
property and equipment
|
-
|
|
7
|
|
-
|
|
3,756
|
Payment of contingent
consideration
|
(5,971)
|
|
(1,238)
|
|
(25,299)
|
|
(24,773)
|
Payment of deferred
consideration
|
-
|
|
-
|
|
(12,375)
|
|
(41,114)
|
Payment of NCI
liability
|
-
|
|
-
|
|
-
|
|
(30,967)
|
Cash used in
investing activities
|
(5,765)
|
|
(3,269)
|
|
(39,116)
|
|
(103,926)
|
|
|
|
|
|
|
|
|
Cash flows (used in)
from financing activities
|
|
|
|
|
|
|
|
Transfers from
restricted cash
|
-
|
|
3,162
|
|
-
|
|
5,230
|
Interest
paid
|
(5,637)
|
|
(7,938)
|
|
(23,767)
|
|
(33,724)
|
Dividends
paid
|
(2,852)
|
|
(2,042)
|
|
(10,777)
|
|
(6,156)
|
Payment of lease
liabilities
|
(4,967)
|
|
(5,427)
|
|
(19,760)
|
|
(20,626)
|
Repurchase of common
shares
|
(17,713)
|
|
(2,094)
|
|
(71,506)
|
|
(17,388)
|
Stock options
exercised
|
-
|
|
-
|
|
875
|
|
-
|
Repayment of notes
payable
|
-
|
|
(40)
|
|
(39)
|
|
(159)
|
Net repayment of
borrowings
|
(61,502)
|
|
(29,882)
|
|
(139,848)
|
|
(40,475)
|
Cash used in
financing activities
|
(92,671)
|
|
(44,261)
|
|
(264,822)
|
|
(113,298)
|
|
|
|
|
|
|
|
|
Net change in cash
during the period
|
(41,463)
|
|
66,951
|
|
(34,557)
|
|
12,316
|
Effect of foreign
exchange on cash
|
3,732
|
|
(1,753)
|
|
7,945
|
|
(1,787)
|
Cash derecongnized on
loss of control of Portage
|
-
|
|
-
|
|
(1,074)
|
|
-
|
Cash, beginning of the
period
|
180,464
|
|
105,221
|
|
170,419
|
|
159,890
|
Cash, end of the
period
|
142,733
|
|
170,419
|
|
142,733
|
|
170,419
|
__________
|
1
|
This is a Non-IFRS
measure (including non-IFRS ratio or supplementary financial
measure) and not a recognized, defined or standardized measure
under IFRS. See the "Non-IFRS Financial Measures" section of this
press release for definitions, uses and a reconciliation of
historical non-IFRS financial measures to the most directly
comparable IFRS financial measures.
|
Non-IFRS Financial Measures
This press release refers to certain performance indicators
including Adjusted EBITDA, gross sales, gross sales organic growth,
return of capital, net debt, leverage ratio, adjusted net income
("Adjusted Net Income") and adjusted earnings per share
("Adjusted EPS") that do not have any standardized meaning
prescribed by IFRS and may not be comparable to similar measures
presented by other companies. Management believes that these
measures are useful to most shareholders, creditors, and other
stakeholders in analyzing the Company's operating results and can
highlight trends in its core business that may not otherwise be
apparent when relying solely on IFRS financial measures. The
Company also believes that securities analysts, investors and other
interested parties frequently use non-IFRS measures in the
evaluation of issuers.
Management also uses non-IFRS measures in order to facilitate
operating performance comparisons from period to period, prepare
annual operating budgets and assess the ability to meet capital
expenditure and working capital requirements. These non-IFRS
financial measures should not be considered as an alternative to
the consolidated income (loss) or any other measure of performance
under IFRS. Investors are encouraged to review the Company's
financial statements and disclosures in their entirety, are
cautioned not to put undue reliance on non-IFRS measures and view
them in conjunction with the most comparable IFRS financial
measures.
Please see "Non-IFRS Financial & Supplementary Financial
Measures" and "Summary of Consolidated Financial Results" in the
Company's most recent Management's Discussion and Analysis, which
is available on the Company's profile on SEDAR+ at
www.sedarplus.ca, for further details on certain non-IFRS measures,
which information is incorporated by reference herein.
Adjusted EBITDA
Adjusted EBITDA represents net income or loss adjusted to
exclude amortization, depreciation, net finance expense, foreign
exchange gains and losses, other expenses and income, share-based
compensation expense, income tax expense or recovery, change
in fair value of contingent consideration, impairment loss, gain or
loss on loss of control of subsidiary, income or loss from
investment in associates and acquisition, integration,
restructuring and other expenses. Acquisition and transaction
related costs primarily consists of acquisition-related
compensation tied to continued employment of pre-existing
shareholders of the acquiree not included in the total purchase
consideration and professional fees. Integration costs primarily
consist of professional fees incurred related to integration of
acquisitions completed. Restructuring costs mainly represent
employee exit costs as a result of synergies created from
acquisitions and organizational changes.
Adjusted EBITDA is not a recognized, defined, or standardized
measure under IFRS. The Company's definition of Adjusted EBITDA
will likely differ from that used by other companies and therefore
comparability may be limited.
Adjusted EBITDA should not be considered a substitute for or in
isolation from measures prepared in accordance with IFRS.
The IFRS measure most directly comparable to Adjusted
EBITDA presented in the Company's financial statements is net
(loss) income before taxes.
The Company has reconciled Adjusted EBITDA to the most
comparable IFRS financial measure as follows:
|
|
Three months
ended
December 31,
|
|
Fiscal year
ended
December 31,
|
In
$000s
|
2024
$
|
|
2023
$
|
|
2024
$
|
|
2023
$
|
Net (loss) income
before taxes
|
(21,206)
|
|
(4,454)
|
|
(200,517)
|
|
(18,565)
|
Depreciation and
amortization
|
20,283
|
|
29,212
|
|
89,665
|
|
111,451
|
Depreciation included
in cost of sales
|
3,296
|
|
2,427
|
|
10,791
|
|
8,532
|
Finance expense,
net
|
8,098
|
|
10,355
|
|
30,979
|
|
41,225
|
Acquisition,
integration, restructuring and other
|
5,737
|
|
2,679
|
|
16,429
|
|
13,648
|
Change in fair value of
contingent consideration
|
6,293
|
|
5,464
|
|
10,582
|
|
14,673
|
Share-based
compensation
|
1,185
|
|
954
|
|
5,858
|
|
3,692
|
Other loss (income),
net
|
237
|
|
(132)
|
|
1,357
|
|
(4,362)
|
Loss on loss of control
of Portage
|
-
|
|
-
|
|
117
|
|
-
|
Loss from investment in
associates
|
23,962
|
|
-
|
|
25,930
|
|
-
|
Impairment loss –
Germany segment
|
-
|
|
-
|
|
176,124
|
|
-
|
Adjusted
EBITDA
|
47,885
|
|
46,505
|
|
167,315
|
|
170,294
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA as a % of Gross Profit
The Company believes that Adjusted EBITDA as a % of gross profit
is a useful measure of the Company's operating efficiency and
profitability. This is calculated by dividing Adjusted EBITDA by
gross profit.
Adjusted Net Income and Adjusted EPS
Adjusted Net Income represents net income or loss adjusted to
exclude acquisition, integration, restructuring and other expenses,
change in fair value of contingent consideration, impairment loss,
gain or loss on loss of control of subsidiary, income or loss from
investment in associates, amortization of acquired intangible
assets, unrealized foreign exchange gain or loss, and share-based
compensation. The Company believes that Adjusted Net Income is a
more useful measure than net income as it excludes the impact of
one-time, non-cash and/or non-recurring items that are not
reflective of Converge's underlying business performance. Adjusted
EPS is calculated by dividing Adjusted Net Income by the total
weighted average shares outstanding on a basic and diluted
basis. The IFRS measure most directly comparable to Adjusted
Net Income presented in the Company's financial statements is net
income (loss) and net income (loss) per share. The Company has
provided a reconciliation to the most comparable IFRS financial
measure as follows:
|
Three months
ended
December 31,
|
|
Fiscal year
ended
December 31,
|
In $000s except per
share amounts
|
2024
$
|
|
2023
$
|
|
2024
$
|
|
2023
$
|
Net loss
|
(9,174)
|
|
4,781
|
|
(180,986)
|
|
(6,393)
|
Acquisition,
integration, restructuring and other
|
5,737
|
|
2,679
|
|
16,429
|
|
13,648
|
Change in fair value of
contingent consideration
|
6,293
|
|
5,464
|
|
10,582
|
|
14,673
|
Amortization on
intangibles
|
17,386
|
|
24,468
|
|
75,158
|
|
87,259
|
Foreign exchange loss
(gain)
|
197
|
|
(132)
|
|
1,077
|
|
(4,480)
|
Share-based
compensation
|
1,185
|
|
954
|
|
5,858
|
|
3,692
|
Loss on loss of control
or Portage
|
-
|
|
-
|
|
117
|
|
-
|
Loss from investment in
associates
|
23,962
|
|
-
|
|
25,930
|
|
-
|
Impairment loss-
Germany segment
|
-
|
|
-
|
|
176,124
|
|
-
|
Adjusted Net
Income
|
45,586
|
|
38,214
|
|
130,289
|
|
108,399
|
Adjusted EPS -
Basic
|
0.23
|
|
0.19
|
|
0.66
|
|
0.53
|
Return of capital
The Company calculates return of capital to shareholders as the
total of cash used in dividend payments and share repurchases.
Net Debt
The Company calculates net debt1 as current and
non-current borrowings less cash.
Leverage Ratio
The Company defines leverage ratio as net debt (current and
non-current borrowings less cash) divided by trailing twelve months
Adjusted EBITDA.
Gross sales and gross sales organic growth
Gross sales, which is a non-IFRS measure, reflects the gross
amount billed to customers, adjusted for amounts deferred or
accrued. The Company believes gross sales is a useful alternative
financial metric to net revenue, the IFRS measure, as it better
reflects volume fluctuations as compared to net revenue. Under the
applicable IFRS 15 'principal vs agent' guidance, the principal
records revenue on a gross basis and the agent records commission
on a net basis. In transactions where Converge is acting as an
agent between the customer and the vendor, net revenue is
calculated by reducing gross sales by the cost of sale
amount.
The Company has provided a reconciliation of gross sales to
revenue, which is the most comparable IFRS financial measure, as
follows:
|
Three months
ended
December 31,
|
|
Fiscal year
ended
December 31,
|
In
$000s
|
2024
$
|
|
2023
$
|
|
2024
$
|
|
2023
$
|
|
|
|
|
|
|
|
|
Product
|
811,839
|
|
719,974
|
|
2,898,039
|
|
2,747,172
|
Managed services and
professional services
|
119,128
|
|
138,001
|
|
472,535
|
|
522,827
|
Maintenance, support,
and cloud solutions
|
175,088
|
|
220,688
|
|
750,143
|
|
767,922
|
Gross sales
|
1,106,055
|
|
1,078,663
|
|
4,120,717
|
|
4,037,921
|
Less: adjustment for
sales transacted as agent
|
425,277
|
|
427,573
|
|
1,528,636
|
|
1,332,714
|
Revenue
|
680,778
|
|
651,090
|
|
2,592,081
|
|
2,705,207
|
Organic growth
The Company measures organic growth on a quarterly and
year-to-date basis, at the gross sales and gross profit levels, and
includes the contributions under Converge ownership in the current
and comparative period(s). In calculating organic growth, the
Company therefore deducts gross sales and gross profit generated
from all corresponding prior period comparable pre-acquisition
period(s) from the current reporting period(s) included in the
consolidated results.
Organic growth calculation for the three months and fiscal year
ended December 31, 2024, deducts
gross sales and gross profits from Portage CyberTech Inc.
("Portage") for the three and six months ended December 31, 2023 due to deconsolidation of
Portage on June 27, 2024.
Gross profit organic growth is calculated by deducting prior
period gross profit, as reported in the Company's public filings,
from current period gross profit for the same portfolio of
companies. Gross profit organic growth percentage is calculated by
dividing organic growth by prior period reported gross profit.
|
Three months
ended
December 31,
|
|
Fiscal year
ended
December 31,
|
In
$000s
|
2024
$
|
|
2023
$
|
|
2024
$
|
|
2023
$
|
Gross sales
|
1,106,055
|
|
1,078,663
|
|
4,120,717
|
|
4,037,921
|
Less: gross sales from
companies not owned in comparative period
|
-
|
|
17,286
|
|
-
|
|
611,045
|
Gross sales of
companies owned in comparative period
|
1,106,055
|
|
1,061,377
|
|
4,120,717
|
|
3,426,876
|
Less: prior period
gross sales(i)
|
1,074,132
|
|
956,803
|
|
4,028,409
|
|
3,090,981
|
Organic Growth -
$
|
31,923
|
|
104,574
|
|
92,308
|
|
335,895
|
Organic Growth -
%
|
3.0 %
|
|
10.9 %
|
|
2.3 %
|
|
10.9 %
|
(i)
|
For the three months
ended December 31, 2024, Portage prior period gross sales of
$4,531 is excluded and for the fiscal year ended December 31, 2024,
Portage prior period gross sales1 of $9,512 is
excluded.
|
Gross profit organic growth is calculated by deducting prior
period gross profit, from current period gross profit for the same
portfolio of companies. Gross profit organic growth percentage is
calculated by dividing organic growth by prior period reported
gross profit.
|
Three months ended December
31,
|
|
Fiscal
year ended December
31,
|
In
$000s
|
2024
$
|
|
2023
$
|
|
2024
$
|
|
2023
$
|
Gross profit
|
178,629
|
|
181,529
|
|
691,442
|
|
702,880
|
Less: gross profit from
companies not owned in comparative period
|
-
|
|
3,032
|
|
-
|
|
107,295
|
Gross profit of
companies owned in comparative period
|
178,629
|
|
178,497
|
|
691,442
|
|
595,585
|
Less: Prior period
gross profit(i)
|
178,656
|
|
168,916
|
|
696,556
|
|
550,767
|
Organic Growth -
$
|
(27)
|
|
9,581
|
|
(5,114)
|
|
44,818
|
Organic Growth -
%
|
-
|
|
5.7 %
|
|
(0.7 %)
|
|
8.1 %
|
(i)
|
For the three months
ended December 31, 2024, Portage prior period gross profit
of $2,873 is excluded and for the fiscal year ended December 31,
2024, Portage prior period gross profit of $6,324 is
excluded.
|
Forward-Looking Information
This press release contains certain "forward-looking
information" and "forward-looking statements" (collectively,
"forward-looking statements") within the meaning of applicable
Canadian securities legislation regarding Converge and its
business. Any statement that involves discussions with respect to
predictions, expectations, beliefs, plans, projections, objectives,
assumptions, future events or performance (often but not always
using phrases such as "expects", or "does not expect", "is
expected" "anticipates" or "does not anticipate", "plans",
"budget", "scheduled", "forecasts". "estimates", "believes" or
"intends" or variations of such words and phrases or stating that
certain actions, events or results "may" or "could", "would",
"might" or "will" be taken to occur or be achieved) are not
statements of historical fact and may be forward-looking
statements.
Specifically, statements regarding the Transaction, anticipated
timing of the special meeting of shareholders in respect of the
Transaction, the delisting from the TSX and ceasing to be a to be a
reporting issuer under Canadian securities laws , are
considered forward-looking information. The foregoing demonstrates
Converge's objectives, which are not forecasts or estimates of its
financial position, but are based on the implementation of its
strategic goals, growth prospects, and growth initiatives. The
forward-looking information are based on management's opinions,
estimates and assumptions, including, but not limited to:
assumptions as to the ability of the parties to the Transaction to
receive, in a timely manner and on satisfactory terms, the
necessary regulatory, court and shareholder approvals; the ability
of the parties to satisfy, in a timely manner, the other conditions
for the completion of the Transaction, and other expectations and
assumptions concerning the proposed Transaction. The anticipated
dates indicated may change for a number of reasons, including the
necessary regulatory and court approvals or the necessity to extend
the time limits for satisfying the other conditions for the
completion of the proposed Transaction.
While these opinions, estimates and assumptions are
considered by the Company to be appropriate and reasonable in the
circumstances as of the date of this press release, they are
subject to known and unknown risks, uncertainties, assumptions and
other factors that may cause the actual results, levels of
activity, performance, or achievements to be materially different
from those expressed or implied by such forward-looking
information.
The forward looking information are subject to significant risks
including, without limitation: the failure of the parties to obtain
the necessary regulatory and court approvals; failure of the
parties to obtain such approvals or satisfy such conditions in a
timely manner; H.I.G's ability to complete the anticipated debt and
equity financing as contemplated by applicable commitment letters
or to otherwise secure favourable terms for alternative financing;
significant transaction costs or unknown liabilities; the ability
of the Board to consider and approve, subject to compliance by the
Company with its obligations under the Arrangement Agreement, a
superior proposal for the Company; the market price of Common
Shares and business generally; potential legal proceedings relating
to the Transaction and the outcome of any such legal proceeding; or
the occurrence of any event, change or other circumstances that
could give rise to the termination of the Arrangement Agreement and
general economic conditions. Failure to obtain the necessary
shareholder, regulatory and court approvals, or the failure of the
parties to otherwise satisfy the conditions for the completion of
the Transaction or to complete the Transaction, may result in the
Transaction not being completed on the proposed terms or at all. In
addition, if the Transaction is not completed, and the Company
continues as an independent entity, there are risks that the
announcement of the Transaction and the dedication of substantial
resources by the Company to the completion of the Transaction could
have an impact on its business and strategic relationships,
including with future and prospective employees, customers,
suppliers and partners, operating results and activities in
general, and could have a material adverse effect on its current
and future operations, financial condition and prospects. If any of
these risks or uncertainties materialize, or if the opinions,
estimates or assumptions underlying the forward-looking information
prove incorrect, actual results or future events might vary
materially from those anticipated in the forward-looking
information. Although the Company has attempted to identify
important risk factors that could cause actual results to differ
materially from those contained in forward-looking information,
there may be other risk factors not presently known to the Company
or that the Company presently believes are not material that could
also cause actual results or future events to differ materially
from those expressed in such forward-looking information.
There can be no assurance that such information will prove to be
accurate, as actual results and future events could differ
materially from those anticipated in such information. No
forward-looking statement is a guarantee of future results.
Accordingly, you should not place undue reliance on forward-looking
information, which speaks only as of the date made. The
forward-looking information contained in this press release
represents the company's expectations as of the date specified
herein, and are subject to change after such date. However, the
Company disclaims any intention or obligation or undertaking to
update or revise any forward-looking information or to publicly
announce the results of any revisions to any of those statements,
whether as a result of new information, future events or otherwise,
except as required under applicable securities laws.
All of the forward-looking information contained in this press
release is expressly qualified by the foregoing cautionary
statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/converge-reports-fourth-quarter-and-fiscal-year-2024-results-302393630.html
SOURCE Converge Technology Solutions Corp.